Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Pfizer expands commitment to fight infectious diseases with agreement to acquire PowderMed
Acquisition Marks Strategic Entry Into DNA-Based Vaccines

NEW YORK, and OXFORD, United Kingdom, October 9 -- Pfizer Inc announced today it has entered into an agreement to acquire PowderMed Ltd., a privately held U.K. company specializing in the emerging science of DNA-based vaccines.

PowderMed has developed a unique and proprietary technology to deliver DNA directly to the cells of the body’s immune system and is advancing a promising pipeline of proprietary vaccine candidates for influenza and chronic viral diseases.

“This acquisition is a strategic opportunity to enter the vaccine market and is part of our focus on broadening healthcare solutions for patients,” said Jeffrey B. Kindler, chief executive officer, Pfizer Inc. “There is a critical public health need for new, more effective vaccines to prevent and treat infectious diseases. As understanding of the human immune system continues to grow exponentially, PowderMed is on the leading edge of advances in vaccine technology that may lead to new vaccines for infectious diseases.”

“This acquisition is an example of the fresh approach Pfizer is taking to business development,” said David Shedlarz, vice chairman of Pfizer. “With PowderMed’s novel DNA technology and its portfolio of early-stage vaccine candidates, we are adding high-potential, externally sourced product candidates and technologies to our research and development portfolio.”

Needle-free delivery system produces robust immune response
PowderMed’s vaccine development program is based on its Particle Mediated Epidermal Delivery (PMED) Technology, a needle-free delivery system that delivers DNA-coated microscopic gold particles into the skin using pressurized helium gas. The particles penetrate the epidermal layer of the skin activating cells that in turn trigger an immune response. Vaccines based on the PMED technology have been shown to elicit both antibody and cell mediated immune responses, which could lead to improved efficacy compared to traditional vaccines.

New technology has potential advantages over egg-based vaccines
PowderMed is at the forefront of a scientific effort to overhaul a vaccine manufacturing system that has remained largely unchanged for the last 50 years. The current system produces flu vaccine inside chicken eggs, a time-consuming process that takes up to nine months. The process is constrained by limited manufacturing capacity and a limited ability to quickly adapt vaccines to emerging strains of influenza.

PowderMed’s vaccines are being developed in formulations that are stable at room temperature, potentially eliminating the need for cold storage of vaccines. The user-friendly PowderMed delivery device requires minimal medical training and may allow for self-administration.

PowderMed’s DNA-based technology platform has the potential to leapfrog both egg-based vaccine technology and the cell-based vaccine technology currently being developed.

“While the research is at an early stage, DNA-based vaccines may be the next major innovation against the threat of influenza and other chronic viral diseases,” said Dr. John LaMattina, president, Pfizer Global Research and Development. “PowderMed’s technology may lead to new vaccines that are easier to use and store than current vaccines and may have the advantage of being more quickly adaptable to changing strains of influenza.”

Seasonal flu candidate highlights vaccine pipeline
PowderMed has DNA-based influenza vaccines in clinical development for prevention of both seasonal and avian flu. The most advanced candidate is entering Phase II clinical studies for seasonal flu. PowderMed’s pipeline also includes vaccines in Phase I development for herpes simplex virus (HSV) and chronic hepatitis B (HBV) and a preclinical project in genital warts (HPV).

“I am delighted that the potential of the PowderMed technology to revolutionize the prevention and treatment of infectious diseases is now in the hands of the world’s leading pharmaceutica

Publisher Contact Information:

+44 (0) 1865 501 549

Company profile of PowderMed Ltd. (Acquired by Pfizer Inc.)
Past press releases of PowderMed Ltd. (Acquired by Pfizer Inc.).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 21€87.0MInternet services
Feb 21€18.0MInternet commerce
Feb 21€1.6MBusiness applications
Feb 20€6.0MInternet services
Feb 20€4.3MSoftware development
Feb 19€0.4MInternet commerce

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.